228 related articles for article (PubMed ID: 15713418)
1. Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.
Bouzide A; Sauvé G; Yelle J
Bioorg Med Chem Lett; 2005 Mar; 15(5):1509-13. PubMed ID: 15713418
[TBL] [Abstract][Full Text] [Related]
2. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
Kazmierski WM; Andrews W; Furfine E; Spaltenstein A; Wright L
Bioorg Med Chem Lett; 2004 Nov; 14(22):5689-92. PubMed ID: 15482949
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
Ghosh AK; McKee SP; Sanders WM; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC; Huff JR; Anderson PS
Drug Des Discov; 1993; 10(1):77-88. PubMed ID: 8399995
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
Wei Y; Ma CM; Hattori M
Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
[TBL] [Abstract][Full Text] [Related]
9. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureas.
Stranix BR; Sauvé G; Bouzide A; Coté A; Sévigny G; Yelle J; Perron V
Bioorg Med Chem Lett; 2004 Aug; 14(15):3971-4. PubMed ID: 15225709
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
[TBL] [Abstract][Full Text] [Related]
11. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
[TBL] [Abstract][Full Text] [Related]
12. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
14. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
15. Design, biologic evaluation, and SAR of novel pseudo-peptide incorporating benzheterocycles as HIV-1 protease inhibitors.
He M; Zhang H; Yao X; Eckart M; Zuo E; Yang M
Chem Biol Drug Des; 2010 Aug; 76(2):174-80. PubMed ID: 20572811
[TBL] [Abstract][Full Text] [Related]
16. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
Sherrill RG; Furfine ES; Hazen RJ; Miller JF; Reynolds DJ; Sammond DM; Spaltenstein A; Wheelan P; Wright LL
Bioorg Med Chem Lett; 2005 Aug; 15(15):3560-4. PubMed ID: 15975788
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV-1 protease activity of compounds from Boesenbergia pandurata.
Cheenpracha S; Karalai C; Ponglimanont C; Subhadhirasakul S; Tewtrakul S
Bioorg Med Chem; 2006 Mar; 14(6):1710-4. PubMed ID: 16263298
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
